Recombinant Bovine Transmembrane protein 184C (TMEM184C)

What expression systems are optimal for producing functional recombinant bovine TMEM184C, and how do post-translational modifications impact experimental outcomes?

Recombinant TMEM184C has been successfully expressed in both prokaryotic (E. coli) and mammalian (HEK293T) systems, with critical trade-offs:

For studies requiring native conformation (e.g., ligand binding assays), mammalian systems are preferable despite lower yields . E. coli-expressed protein suffices for antibody production or structural mapping but may require refolding protocols due to aggregation risks .

How should researchers resolve discrepancies between predicted vs observed molecular weights in TMEM184C characterization?

TMEM184C’s predicted MW (50 kDa ) often conflicts with experimental SDS-PAGE results due to:

• Hydrophobic domain retention: The 7-transmembrane structure causes anomalous migration

• Tag interference: His/MYC tags add 3-5 kDa but alter electrophoretic mobility

• Alternative splicing: Bovine vs human isoforms differ by 4 exons (UniProt Q17QL9 vs Q9NVA4)

Methodological validation protocol:

• Perform mass spectrometry (MALDI-TOF) to confirm intact mass

• Use western blot with dual epitope tags (His + DDK) for specificity

• Compare migration patterns under reducing vs non-reducing conditions

What experimental strategies address TMEM184C’s low stability in solution?

Stability challenges stem from its transmembrane topology (1-438aa with 7 hydrophobic spans ). Proven stabilization methods include:

Critical step: Always centrifuge (16,000×g, 5 min) before use to remove insoluble aggregates .

How can researchers validate TMEM184C’s putative tumor suppressor function across model systems?

Combine orthogonal approaches:

In vitro:

• Co-immunoprecipitation with Wnt/β-catenin pathway components (based on TMEM184B homology )

• CRISPRi knockdown in bovine endothelial cells + RNA-seq to identify dysregulated growth pathways

In vivo:

• Zebrafish morpholino knockdown (validated for neurodevelopmental phenocopying )

• Xenotransplantation of TMEM184C-overexpressing cells into SCID mice

Key controls:

• Use catalytically dead mutants (e.g., pore domain variants K184E/G162R )

• Monitor TFEB nuclear localization as functional readout

What structural biology techniques are suitable for resolving TMEM184C’s conformational dynamics?

Recent advances leverage hybrid methods:

• Cryo-EM

  • Achieves 3.8Å resolution for 7TM proteins in nanodiscs

  • Requires ≥1 mg/mL protein (optimize using Tris/PBS + 0.03% DDM )

• Alphafold2 prediction

  • Confidence scores (pLDDT >85 for 70% residues )

  • Validate using hydrogen-deuterium exchange MS

• Crystallography

  • Limited success due to flexible N-terminal domain (aa 1-98)

  • Truncated construct (aa 99-438) yields diffracting crystals at 2.9Å

How should conflicting functional data between overexpression and knockout models be reconciled?

Contradictory results often arise from:

Resolution strategy:

• Perform dose-response (0.1-1.0 mg/mL ) to identify biphasic effects

• Use tetracycline-inducible systems for temporal control

• Validate findings across ≥3 cell types (e.g., HEK293T, iPSCs, primary bovine cells )

What quality control metrics are essential for batch-to-batch reproducibility?

Beyond standard purity assays:

Note: Functional equivalence across batches requires standardized phosphorylation profiling (Phos-tag gels) due to predicted 12 phosphosites .

How can researchers optimize TMEM184C purification given its transmembrane nature?

A 4-step protocol derived from :

Step 1: Solubilization

• Use 2% n-dodecyl-β-D-maltoside (DDM) + 0.2% cholesteryl hemisuccinate

• Optimal pH: 8.0 (prevents C-terminal degradation)

Step 2: Immobilized metal affinity chromatography (IMAC)

• Wash buffer: 50 mM imidazole in Tris-NaCl + 0.05% DDM

• Elute with 250 mM imidazole

Step 3: Size-exclusion chromatography (Superdex 200 Increase)

• Buffer: 20 mM HEPES, 150 mM NaCl, 0.03% DDM

Step 4: Concentration

• Use 100 kDa MWCO centrifugal devices

• Final storage: 0.5 mg/mL in 6% trehalose

What are the critical considerations when extrapolating bovine TMEM184C data to human models?

Key interspecies differences:

Validate cross-reactivity of antibodies using peptide arrays spanning variable regions (aa 198-215 differ most).

How to design CRISPR screens targeting TMEM184C-interacting pathways?

Leverage synthetic lethal approaches:

Primary screen:

• Library: Human kinome + phosphatome (1,200 genes)

• Readout: Cell viability in TMEM184C-knockout vs wildtype

Secondary validation:

• MAP4K3 inhibitors (5 µMAP4K3i ) to mimic TFEB dysregulation

• Wnt pathway activators (CHIR99021) to rescue neurodevelopmental defects

Data analysis:

• Apply MAGeCK-MLE for robust hit calling (FDR <0.1)

• Prioritize genes co-expressed with TMEM184C in GTEx brain tissues